Merck & Co., Inc (NYSE:MRK), the second largest U.S. drug-maker
by sales, will eliminate 8,500 employees from its workforce and
refurbish its research and development after U.S. regulators delayed new
medicines.
The Whitehouse Station, New Jersey-based company said in a statement
today that the eliminated positions are in addition to already announced
7,500 employee layoffs. It is accounted for 20 percent of company’s
total workforce. The company refused to provide details about where the
layoffs will occur, and only said that the eliminations would come from
all areas of Merck, including R&D, sales and management. Read More:
No comments:
Post a Comment